Previous 10 | Next 10 |
home / stock / mdgef / mdgef news
Planegg/Martinsried, June 14, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 7 th annual Immuno-Oncology Summit Europe which ...
Planegg/Martinsried, June 13, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will host an R&D Event to discuss the pipeline expansion and the evolution...
Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from solid tumors with high unmet need KRAS TCR-T programs to benefit from combination with Medigeneȁ...
Planegg/Martinsried, May 30, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 i...
Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the Company has been issued a patent by the Japan Patent Offic...
Planegg/Martinsried, May 8, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following upcoming investor conferences: Bio...
Planegg/Martinsried, May 4, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents the webtool Expitope 3.0 at the 20 th Annual Meeting of the Assoc...
2023-05-03 06:27:12 ET Medigene AG press release ( OTCPK:MDGEF ): Q1 Revenue of €1.5M. The Company maintains strong liquidity of EUR 32.1 million cash & cash equivalents in the amount of EUR 21.1 million and time deposits of EUR 11.0 million as of March 3...
Focus on executing the strategic plan and delivering shareholder value MDG1015 pre-clinical data underline potential in solid tumor therapy Subsequent to Q1, expansion of tools and technologies in our end-to-end technology platform Guidance confirmed; cash runway maintained through Q4...
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients with solid tumors CD40L-CD28 costimulatory switch receptor ...
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...